Redeye raises 2020 sales and earnings estimates for Genovis slightly as we believe the company may be managing challenges due to the corona crisis rather well. A genuine quality company with a resilient model, in our view, Genovis should be well positioned to benefit as the world continues to open up. We caution that the current valuation leaves little margin for error, however, and we remind investors that we anticipate no follow-up order in the important Bioprocess area until late 2021. Genovis remains on Redeye's Conviction Buy List.